Prolexys Pharmaceuticals Licenses Novel Anticancer Compounds

Prolexys Pharmaceuticals, a biopharmaceutical company dedicated to the development of novel cancer therapies, has signed an exclusive licensing agreement with the Massachusetts Institute of Technology, acting as licensing agent for the Whitehead Institute for Biomedical Research of Cambridge, Mass., and Columbia University of New York City. The agreement provides Prolexys with exclusive, worldwide rights to a patent estate covering selective antitumor compounds discovered by Brent Stockwell, a former Whitehead Fellow, now an assistant professor of Biological Sciences and Chemistry at Columbia University.

BioSpace

(http://www.biospace.com/news_story.cfm?StoryID=19175220&full=1)